NAMPT — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL157967	1.00	20/20
SCHEMBL81700	0.88	20/20
SCHEMBL158287	0.84	20/20
SCHEMBL158536	0.84	20/20
SCHEMBL158069	0.80	20/20
SCHEMBL158808	0.80	20/20
SCHEMBL157706	0.77	20/20
SCHEMBL158493	0.77	20/20
SCHEMBL158073	0.76	20/20
SCHEMBL157819	0.76	20/20
SCHEMBL157675	0.76	20/20
SCHEMBL158391	0.76	20/20
SCHEMBL158200	0.75	20/20
SCHEMBL158559	0.75	20/20
SCHEMBL158094	0.75	20/20
SCHEMBL158099	0.75	20/20
SCHEMBL157680	0.73	20/20
SCHEMBL157898	0.73	20/20
SCHEMBL158027	0.73	20/20
SCHEMBL158713	0.73	20/20

Clinical trials — most relevant to NAMPT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis	PHASE4	NOT_YET_RECRUITING
Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant	PHASE3	COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study to Assess APO866 for the Treatment of Advanced Melanoma	PHASE2	COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging	PHASE2	RECRUITING
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome	PHASE1/PHASE2	COMPLETED
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD	PHASE2	ACTIVE_NOT_RECRUITING
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia	PHASE1/PHASE2	RECRUITING
Nicotinamide as an Early Alzheimer's Disease Treatment	PHASE2	COMPLETED
Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia	PHASE2	WITHDRAWN
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly	PHASE2	WITHDRAWN
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy	PHASE1	COMPLETED
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery	nan	NOT_YET_RECRUITING
Diurnal Variability in the Regulation of Beta-cell Function and Insulin Sensitivity in Overweight People	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
IV Administration of ChromaDex's Niagen® as Compared to NAD+	nan	UNKNOWN
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations	nan	UNKNOWN
Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity	nan	COMPLETED
Nicotinamide Riboside Clinical Trial for GWI	nan	RECRUITING
Inflammation in COPD and the Effect of Nicotinamide Riboside	nan	COMPLETED
Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients	nan	UNKNOWN
Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults	nan	NOT_YET_RECRUITING
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity	nan	COMPLETED
NOPARK Open Label Extension Study	nan	ACTIVE_NOT_RECRUITING
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NAMPT binder may also engage these)

Protein	Name	Similarity
Q80Z29	—	1.000	Q80Z29 →
Q52I78	—	1.000	Q52I78 →
Q99KQ4	—	0.999	Q99KQ4 →
F4JGR5	—	0.962	F4JGR5 →
Q94AR8	—	0.962	Q94AR8 →
Q5RFG2	—	0.960	Q5RFG2 →
P0AC34	—	0.959	P0AC34 →
P08200	—	0.958	P08200 →
O09171	—	0.958	O09171 →
Q3T0V9	—	0.958	Q3T0V9 →
O80526	—	0.957	O80526 →
P14407	—	0.957	P14407 →
Q9HD40	—	0.956	Q9HD40 →
Q8X4P8	—	0.956	Q8X4P8 →
P21343	—	0.956	P21343 →
Q5M8Z0	—	0.955	Q5M8Z0 →
Q2QZ86	—	0.955	Q2QZ86 →
DERA	Deoxyribose-phosphate aldolase	0.955	landscape →
Q5RDD3	—	0.954	Q5RDD3 →
P0AC33	—	0.954	P0AC33 →
Q32L93	—	0.953	Q32L93 →
Q83SM9	—	0.953	Q83SM9 →
P97789	—	0.953	P97789 →
Q5XGM3	—	0.953	Q5XGM3 →
Q8IZH2	—	0.953	Q8IZH2 →
Q5RAK7	—	0.953	Q5RAK7 →
P55931	—	0.952	P55931 →
P57957	—	0.952	P57957 →
Q99L27	—	0.952	Q99L27 →
O35490	—	0.952	O35490 →